Medical care in patients with heart failure: clinical characteristics, prognostic determinants and follow-up in primary care

N. Soriano Palacios, C. Brotons Cuixart, G. Pernayner Miralda, I. Moral Peláez, I. Alegre Valls and J. Martí Montesa

Objective. To assess the process of care and prognosis of patients with heart failure (HF) attended in a tertiary hospital and follow up at the primary care level.

Design. Prospective study of 18 months of follow up.

Setting. Tertiary hospital and primary care centers of the reference area.

Participants. Patients admitted to a tertiary hospital from the first of July until the 31 of December of 1998.

Outcome measurements. Pharmacological data and morbimortality at discharge and at the end of the follow-up, functional capacity of survivors.

Results. 265 patients were included, with a mean age of 75 years, 57% were females, 73.8% had HF as first diagnosis, 6.1% had MI, and 20% were attended for other medical reasons. The most frequent cause of HF was HTA. Drugs more prescribed at the discharge and follow up were diuretics and ACE inhibitors. Hospital mortality was 6.4% and mortality at the end of the follow-up was 46% (in 77% of those for cardiac reasons). After being discharged 38.5% of the patients were readmitted to the hospital with the diagnosis of HF; 72% were visited by the family physician, 43% at the outpatient clinic and 33% by the cardiologist; 60% of the patients who survived were in I–II NYHA functional class, 76% walked regularly, and 25% did recreational activities and physical exercise.

Conclusions. Patients attended at the hospital with HF are an old population, have frequently associated other chronic diseases, and have a very bad prognosis. These patients spend an important amount of health resources. Drug prescription at the follow up is suboptimum. Patients who survived have an acceptable functional capacity.

Key words: Heart failure. Prognosis. Process of care. Primary care

LA ATENCIÓN MÉDICA DE LOS PACIENTES CON INSUFICIENCIA CARDÍACA: CARACTERÍSTICAS CLÍNICAS, DETERMINANTES DEL PRONÓSTICO Y SEGUIMIENTO EN LA ATENCIÓN PRIMARIA

Objetivo. Analizar el proceso asistencial de los pacientes ingresados con el diagnóstico de insuficiencia cardiaca (IC) y posteriormente durante el seguimiento en la atención primaria.

Diseño. Estudio prospectivo de un año y medio de seguimiento.

Emplazamiento. Hospital terciario y centros de atención primaria del área de referencia.

Participantes. Pacientes diagnosticados de IC al alta hospitalaria desde el 1 de julio hasta el 31 de diciembre de 1998.

Mediciones principales. Datos farmacológicos al alta y al final del seguimiento, morbimortalidad al final del seguimiento, capacidad funcional de los supervivientes.

Resultados. Se incluyó a 265 pacientes. La edad media de los mismos era de 75 años, el 57% eran mujeres, el 73,9% ingresó por IC, el 6,1% por infarto agudo de miocardio (IAM) y el 20% por otros motivos. El factor causal más frecuente fue la hipertensión arterial. Los fármacos más utilizados tanto al alta hospitalaria como en el seguimiento fueron los diuréticos, seguidos de los inhibidores de la enzima conversiva de la angiotensina (IECA). La mortalidad hospitalaria fue del 6,4%, y a los 18 meses de seguimiento, de un 46% (en un 77% de éstos de causa cardíaca). Tras el alta hospitalaria el 38,5% de los pacientes reingresó por IC, el 72% se visitaba por el médico de familia, el 43% en consultas externas del hospital y el 33% por el cardiologo; un 76% caminaba regularmente y el 25% hacia actividades recreacionales y ejercicio físico.

Conclusiones. La población atendida por IC es una población envejecida, con alta comorbilidad y un mal pronóstico, que precisa una cantidad destacable de recursos sanitarios. La prescripción farmacológica en el seguimiento es subóptima. La población superviviente disfruta de una aceptable capacidad funcional.

Introduction

Heart failure (HF) is recognized as an important and increasingly worrisome public health problem in developed countries. The aging of the population along with increased survival of patients with ischemic heart disease or hypertension and other diseases that cause HF mean that the incidence of HF is expected to increase in coming years. Patients with HF require different types of health care (i.e., primary, specialized, and hospital care) and incur considerable costs within the health care system. Despite the problems in obtaining precise data, some studies have estimated a prevalence in Spain of 5.3 per thousand, and a direct annual cost of 64,028 to 110,240 million pesetas, representing between 1.8% and 3.1% of the annual public health budget.

The tendency in Spain toward decreasing mortality and increasing morbidity and hospitalization because of HF indicate a need for improved treatments and follow-up for diseases that cause HF, with the intention of decreasing its prevalence, morbidity and mortality. In addition, these trends illustrate the importance of improving coordination between different levels of care for patients with HF. An earlier study reported the results obtained with regard to hospital care. The present report offers further information in the form of an analysis of the health care process for patients who are hospitalized for HF at a tertiary center, and for surviving patients who are subsequently followed by a primary care service after discharge.

Material and methods

The methods were described in detail in a previous report. In summary, 311 patients with HF were identified as having been discharged between 1 July and 31 December 1998 from a tertiary hospital serving a reference population of 450,000 inhabitants. Heart failure (code 428 in the International Classification of Disease, Ninth Revision) was the first, second or third diagnosis. The diagnosis of HF was confirmed, on the basis of a slight evidence of systemic venous hypertension. Patients with HF from a reversible cause, with terminal illness, or who resided abroad (and hence could not be followed for the full study period) were excluded. Patients seen in the emergency room but not admitted were also excluded because of difficulties in obtaining full clinical information for the present study.

Of the 311 patients identified whose hospital record was reviewed, 265 fulfilled all inclusion criteria (85.2%). The hospital records were reviewed to note demographic, clinical and pharmacological data, and status upon discharge. Clinical and pharmacological data, and information on factors related with quality of life 18 months after discharge, were obtained with systematic telephone interviews. Some primary care center records were reviewed to verify the responses given in the telephone interview.

General scheme of the study

Observational, prospective 18-month study of patients with a diagnosis of heart failure on hospital discharge

A total of 227 patients or relatives were contacted by phone (some after several tries); 8% were lost to follow-up. To validate the information regarding cause of death obtained from the telephone interview, the hospital record was reviewed for patients who died during a subsequent hospital readmission.

A descriptive analysis was done for all variables by calculating the frequency distribution for discrete variables, or the mean and standard deviation for continuous variables. Univariate analysis was used to compare the clinical characteristics of surviving patients who were discharged but who died during follow-up and discharged patients who were still alive at the end of follow-up. To compare the characteristics of patients with a good and a poor prognosis at the end of the follow-up period, the chi-squared test was used for qualitative variables, and Student’s t test was used for continuous variables. Multivariate analysis with the Cox proportional risks model used mortality during follow-up as the dependent variable. As independent variables we used those demographic, clinical and treatment variables of relevance to the
course of the disease that showed a significant relationship in the univariate analysis.

Results

The clinical outcomes in our sample of hospitalized patients were published in an earlier article. Briefly, the final number of patients included was 265; 57% were women and 43% were men, and mean age was 75 years. Almost 40% of the patients were more than 80 years old, and more than 70% were older than 70 years. Retired persons made up 85% of the sample; 12% were actively employed and 3% were incapacitated. The main cause of hospitalization was HF in 73.5% of the patients; 7.5% were admitted because of acute myocardial infarction, and the remaining 19% were hospitalized for a variety of reasons such as pneumonia or other respiratory disease, cerebrovascular accident or surgery. More than half (58%) were admitted through the internal medicine service, and 21% were admitted through the cardiology service; the latter patients were predominantly men and were younger than the mean age of the sample as a whole. The remaining 21% were admitted through other hospital services. Hospital mortality was 6.4%.

Table 1 shows the main clinical findings on discharge in surviving patients. There were antecedents of HF in 69% of the patients; the prevalence of hypertension was 54.8%, a previous history of angina was recorded in 25.4%, and a previous history of infarction was present in 22.6%.

Significant underlying disease (e.g., chronic renal failure, neoplasm, cerebral or peripheral vascular ischemic disease) was present in 62.5% of the patients.

At the time of hospitalization 87% of the patients were classified as NYHA functional class III-IV, 24% were admitted for clinically acute pulmonary edema, and 56% had global HF.

The causal factors of HF identified were hypertension in 50% of the patients, coronary disease in 33.8%, valvular disorder in 23.4% (not related to valve replacement or already treated surgically), cardiomyopathy in 6.1%, and other factors in 3.2% (chemotherapy toxicity, congenital disease, amyloidosis). The underlying cause was unknown in 13.3% of the patients.

Electrocardiogram and chest x-ray were done in all patients. Ventricular function was evaluated in 67.7% (echocardiography, isotopic ventriculography or coronary arteriography done before or during hospitalization or during follow-up); the results showed normal function in 42.3% of the patients (ejection fraction >50%), slightly (ejection fraction 50%-40%) or moderately impaired function (ejection fraction 39%-30%) in 35.7%, and severe impairment (ejection fraction <30%) in 22%. Ventricular function was calculated in 92.2% of the patients younger than 75 years and in 50.7% of those older than 75 years; in 78.3% of the men and 59.8% of the women, and in 93.5% of all patients admitted through the cardiology service vs. 61.8% of the patients admitted through other services.

The drugs used most often on discharge were diuretics (93%) and ACE inhibitors (48%). Digitalis was used by 38% of the patients, and beta-blockers (carvedilol and others) by 4%. Angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists (ARA-II) were prescribed for 61.3% of the patients for whom ventricular function had been determined, vs. 38.7% of those who had not undergone this test; these drugs were also prescribed for 72.2% of the patients with impaired ventricular function vs. 46.5% of those with normal functioning. There were no differences in the use of ACE inhibitors or ARA-II between patients older and younger than 75 years.

Results of follow-up

Follow-up data were obtained for 122 surviving patients; for patients who died, data were obtained only for cause of death. Overall mortality was 46.2%. In 76.8% of the patients the cause of death was heart disease; in the remaining 23.2% other causes were identified (e.g., neoplasm, cerebrovascular accident or renal failure). Mean age of the patients at the time of death was 80 years; mean age of

---

<table>
<thead>
<tr>
<th>TABLE 1</th>
<th>Initial clinical and demographic characteristics of the study population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population, number</td>
<td>248</td>
</tr>
<tr>
<td>Mean age, years</td>
<td>75 (25-98)</td>
</tr>
<tr>
<td>Women</td>
<td>57%</td>
</tr>
<tr>
<td>Antecedents of heart failure</td>
<td>68.9%</td>
</tr>
<tr>
<td>Hypertension I</td>
<td>54.8%</td>
</tr>
<tr>
<td>Prior acute myocardial infarction</td>
<td>22.6%</td>
</tr>
<tr>
<td>Prior angina</td>
<td>25.4%</td>
</tr>
<tr>
<td>Valve disorder</td>
<td>22.9%</td>
</tr>
<tr>
<td>Diabetes</td>
<td>35.1%</td>
</tr>
<tr>
<td>Reason for hospitalization</td>
<td>73.8%</td>
</tr>
<tr>
<td>Heart failure</td>
<td>73.8%</td>
</tr>
<tr>
<td>Acute myocardial infarction</td>
<td>6.1%</td>
</tr>
<tr>
<td>Other</td>
<td>20.1%</td>
</tr>
<tr>
<td>Functional class according to NYHA</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>2.5%</td>
</tr>
<tr>
<td>II</td>
<td>10.5%</td>
</tr>
<tr>
<td>III</td>
<td>34.8%</td>
</tr>
<tr>
<td>IV</td>
<td>52.2%</td>
</tr>
<tr>
<td>Clinically acute pulmonary edema</td>
<td>23.7%</td>
</tr>
<tr>
<td>Global heart failure</td>
<td>56.1%</td>
</tr>
<tr>
<td>Comorbidity</td>
<td>62.5%</td>
</tr>
</tbody>
</table>

*In most patients, pneumonia or other respiratory infection, cerebrovascular accident and surgery.

*Neoplasm, renal failure, cerebral or peripheral ischemic disease.
soriano palacios n, brotons cuixart c, permanyer miralda g, moral peláez i, alegre valls i and martí montesa j.–
medical care in patients with heart failure: clinical characteristics, determinants of prognosis and follow-up in primary care

Changes in pharmacological treatment during follow-up

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Discharge&lt;sup&gt;a&lt;/sup&gt; (n = 248)</th>
<th>Discharge&lt;sup&gt;b&lt;/sup&gt; (n = 122)</th>
<th>18 months</th>
<th>% change&lt;sup&gt;c&lt;/sup&gt;</th>
<th>New drugs</th>
<th>Drugs stopped</th>
<th>Non compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diuretics</td>
<td>93%</td>
<td>88.5%</td>
<td>83%</td>
<td>13%</td>
<td>4%</td>
<td>7%</td>
<td>2%</td>
</tr>
<tr>
<td>Digitalis</td>
<td>38%</td>
<td>34%</td>
<td>37%</td>
<td>13%</td>
<td>7%</td>
<td>4%</td>
<td>2%</td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>48%</td>
<td>52%</td>
<td>46%</td>
<td>18%</td>
<td>5.8%</td>
<td>10.6%</td>
<td>1.6%</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>2%</td>
<td>3%</td>
<td>3%</td>
<td>3.2%</td>
<td>1.6%</td>
<td>1.6%</td>
<td>0</td>
</tr>
<tr>
<td>Calcium antagonists</td>
<td>13%</td>
<td>20%</td>
<td>17%</td>
<td>6%</td>
<td>3%</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Vasodilators</td>
<td>40%</td>
<td>40%</td>
<td>35%</td>
<td>13%</td>
<td>4%</td>
<td>6.5%</td>
<td>2%</td>
</tr>
<tr>
<td>Carvedilol</td>
<td>2%</td>
<td>2%</td>
<td>4%</td>
<td>3%</td>
<td>2%</td>
<td>1%</td>
<td>0</td>
</tr>
<tr>
<td>ARA II</td>
<td>6%</td>
<td>7%</td>
<td>12%</td>
<td>9%</td>
<td>7%</td>
<td>2%</td>
<td>0</td>
</tr>
<tr>
<td>Spironolactone</td>
<td>0</td>
<td>0</td>
<td>13%</td>
<td>13%</td>
<td>13%</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

<sup>a</sup>Total population (excluding patients who died in the hospital).
<sup>b</sup>Patients surviving at the end of follow-up.
<sup>c</sup>New drugs added, drugs stopped, and noncompliance.

visits to physicians after hospital discharge

<table>
<thead>
<tr>
<th>Visits to physicians after hospital discharge</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family physician and other specialists</td>
</tr>
<tr>
<td>Hospital out-patient clinics and other specialists</td>
</tr>
<tr>
<td>Cardiologist and other specialists</td>
</tr>
<tr>
<td>Family physician and cardiologist</td>
</tr>
<tr>
<td>Family physician and hospital out-patient clinics</td>
</tr>
<tr>
<td>Family physician only</td>
</tr>
<tr>
<td>Hospital out-patient clinics only</td>
</tr>
<tr>
<td>Cardiologist only</td>
</tr>
<tr>
<td>Private physician only</td>
</tr>
<tr>
<td>Social health center only</td>
</tr>
<tr>
<td>Not seen by any physician</td>
</tr>
</tbody>
</table>

survivors was 72 years. Of the latter, 60% were classified as functional class I–II, in contrast to the high percentage of patients in class III–IV at the time of hospitalization.
During the 18-month follow-up period 38.5% of the patients were hospitalized for HF; of these, 40% were seen in the emergency room (58% of the patients were seen 2 or more times in this service) and 60% were admitted (34% of these patients were admitted 2 or more times). Surgical treatment was used in 7% of the patients; of these, 86% underwent valve replacement and 14% underwent myocardial revascularization. Only 1 patient was awaiting heart transplantation. After discharge ventricular function was evaluated in 28.7% of the patients; testing was done in the hospital in most cases, whereas ventricular function was evaluated at a primary care service in only 6% of the surviving patients. The results were normal in 58% of the patients, and revealed slight or moderate impairment in 29% and severe impairment in 13%.
Pharmacological treatment during the 18-month follow-up period did not differ substantially from the treatment prescribed upon discharge. As shown in Table 2, the most frequent modification in drug prescription involved the ACE inhibitors (18%), which were stopped most frequently (10.6%) because of side effects (1.6%) or substituted with other drugs (9%). The drug added most frequently to the follow-up treatment regimen was spironolactone (13%). During the 18-month follow-up period most patients were seen by at least one physician, and often by a specialist in addition to the general practitioner (Table 3). The family physician was consulted most often (mean of 6 visits), followed by hospital out-patient clinic staff (mean of 4 visits, although it should be noted that 19% of these patients were participating in clinical trials) and cardiologists (mean of 3 visits). Seven percent of the patients consulted their private physician, 5% were living in a social health center and 2% were not seen by any physician after hospital discharge. Altogether, the patients made a total of 543 visits to family physicians, 161 visits to hospital out-patient clinics, and 118 visits to cardiologists. Of the primary care centers where patients were seen, 74% were operating under the new, reformed system; the remainder were operating under the previous set of regulations for the provision of primary care through the Spanish national health system.
Of all surviving patients, 76.4% went out and walked regularly, and 24.7% practiced some type of recreational activity and physical exercise. These results are consistent with the percentage of patients who enjoyed an acceptable functional capacity.
Multivariate analysis showed that the best predictors of mortality after 18 months were age 75 years or older, global HF and comorbidity (Table 4).
The results of this study confirm that in our reference area, HF affects mainly elderly patients; the prognosis is most likely to be poor in patients older than 75 years, as reported in earlier studies. \(^7,8\) The notable influence of comorbidity on the prognosis is clearly illustrated by the fact that 20% of the patients hospitalized for HF died of causes other than heart disease. An antecedent of noncardiac disease at the time of hospitalization was a predictor of mortality, and among half of the patients hospitalized for causes other than HF or acute myocardial infarction died of HF. The overall mortality rate in these patients was similar to that in patients admitted for HF. However, these data should be considered with caution because they were obtained by telephone interview, and because one of the noncardiac causes was cerebrovascular accident, which may well have been a complication of underlying heart disease. Nevertheless, as noted earlier, the reliability of the telephone survey data was verified in a small subgroup of patients who died during a subsequent hospital readmission, as many of these patients died of noncardiac causes. Our results suggest that the role of comorbidity is important, and this factor should be evaluated in depth in patients with HF not only because of its influence on the prognosis, but also because it may affect the approach to therapy.

A possible limitation of this study is the fact that we were dealing with a population of hospitalized patients discharged with a diagnosis of HF. Other published studies have centered on the diagnosis and follow-up of patients with HF in the community, and their results therefore can not readily be compared with ours. A study of patients in Olmsted County, Minnesota (U.S.A.) \(^9\) of the incidence and prognosis in patients with HF identified 216 patients and found a 1-year survival rate of 76%, a figure much higher than our 18-month survival rate. However, another population-based study --the Framingham study \(^10\)-- identified 652 individuals with HF and found a 1-year survival rate of 57% in men and 64% in women, figures closer to (in fact, slightly lower than) ours, and somewhat hard to explain.

Although pharmacological treatment during follow-up in survivors did not vary in overall terms from that prescribed upon hospital discharge, some changes are worth mentioning. Angiotensin-converting enzyme inhibitors were stopped in 10% of our patients (almost always because of side effects), and were added to the regimen in 5.8% of the patients. Angiotensin receptor antagonists were added to the regimen in 7% of the patients (almost always as a substitute for ACE inhibitors). Side effects from ACE inhibitors are not infrequent. A recent systematic review \(^11\) found a 30% rate of undesirable effects for these drugs, which had to be stopped in 15% of the patients (twice the rate found for the placebo). Spironolactone was introduced only during follow-up treatment: no patient was taking this drug upon discharge, whereas it was later prescribed for 13% of the patients. The change in treatment may reflect the publication of the RALES study, \(^12\) which appeared during the follow-up period of the present study. This clinical trial showed that mortality was lower in patients with NYHA grade III-IV HF and ejection fraction <0.55; moreover, all patients were also taking ACE inhibitors and loop diuretics. However, the results of the RALES study were not translated to clinical practice strictly as reported: 62.5% of the patients treated with spironolactone had class I-II impairment, and only 37.5% were taking ACE inhibitors (although most --87.5%-- were also taking diuretics). Ejection fraction had been measured in only 44% of these patients, of whom 57% had normal or only slightly reduced function. These figures illustrate that the extrapolation of the results of clinical trials to practice is not always linear, for different reasons ranging from inadequate knowledge of the scientific evidence (possibly leading to over-reliance as well as to under-reliance on the findings) to a conscientious, reasoned use of the evidence, which in the case of spironolactone might reflect an actual clinical need. A current paradox in the treatment of HF is that the main results of clinical trials refer to improvements in survival, whereas the practicing physician’s priority is to improve symptoms.

Beta-blockers are another group of drugs whose use was unchanged between discharge and follow-up, although in this case the most notable finding was their relatively low use. At the time our patients were discharged, an earlier clinical trial \(^13\) had shown these drugs to be beneficial, and by the end of the follow-up period additional studies likewise reporting positive findings had appeared. \(^14,15\) The use of beta-blockers may be influenced by other factors such as the classic notion --possibly persisting to this day-- that these drugs are contraindicated in HF, or the difficulties involved in titrating the dose over a number of periodic visits.

An analysis of usage of medical services during the follow-up period shows that HF consumes a non-negligible amount of health care resources. The practitioners most often responsible for these patients are family physicians, although in 48% of the patients care was shared with cardiologists or hospital out-patient clinics. This finding is
indirect evidence of some degree of coordination between levels of care, although a more specific study would be needed to describe the quality of the process. About 25% of the population of surviving patients took part in recreational activities and physical exercise. This finding is consistent with existing evidence of the prescription of physical exercise for these patients, and although the data are not very robust, it appears that exercise improves functional capacity and quality of life. The factors that predicted mortality in the present study - age and clinical severity - do not differ substantially from those found in earlier reports. One study in our setting found that the most important predictors of hospital mortality were myocardial infarction, hyponatremia and renal failure. A remarkable fact is that simple clinical markers such as biventricular HF or comorbidity carry more weight than do coronary disease or degree of ventricular function impairment, a finding also reported by others. Among the limitations of the present study are its local nature and the uncertainties surrounding the applicability of our findings to the entire population of patients with HF, as our patients were selected as having been discharged from the hospital. Nevertheless, it is worth emphasizing the consistency between our results and those of other populations of hospitalized patients in a variety of other distant settings. This suggests that our findings are valid for this type of population. In conclusion, patients hospitalized for HF and followed by primary care services comprised an elderly population with a high percentage of comorbidity. Hypertension was the most frequent risk factor, and the prognosis at one and a half years of follow-up was very poor. Prescribing practices during the follow-up period can be considered suboptimal.

Acknowledgments

We thank Aida Ribera Solé, Purificación Cascant Castelló, Josep Pinar Sopena and Marius Morlans Molina of the Vall d’Hebron University Hospital, Barcelona, and X. Mundet Tuduri of the El Carmel Primary Care Center for their contributions to the study design, statistical analysis and writing of the manuscript. The research was financed in part by the Agència d’Avaluació de Tecnología Mèdica (12/15/98) of the Catalonian Department of Health and Social Security.

What is known about the subject

- The population followed for heart failure comprises elderly patients with a high rate of comorbidity.
- The prognosis after one and a half years of follow-up is very poor (almost 50% of the patients had died by this time).

What this study contributes

- Functional capacity of survivors is acceptable.
- Prescribing practices at the end of follow-up are suboptimal.
- The family physician is the care provider most often responsible for follow-up, although for almost half of the patients, care is shared with cardiologists or hospital out-patient clinics.

Reference


COMMENTARY

Care provided to patients with heart failure

J.M. Lobos Bejarano
Family Physician and Coordinator, Spanish Society of Family and Community Medicine Group on Cardiovascular Disease.

Heart failure (HF) is currently the only one of the cardiovascular syndromes with profound public health implications whose incidence is on the rise. The increase can be traced to aging of the population and the increased survival of patients with ischemic heart disease. The prevalence of HF in the general population is estimated at 0.5% to 2%, and increases to 6% in persons older than 65 years and to as much as 10% among those older than 75 years. In the last 15 years the prevalence of HF has doubled, and this trend will continue in the coming years.\(^1\)

In Spain, HF causes around 20% of all deaths from cardiovascular disease and is the most frequent reason for hospitalization among persons older than 65 years. The number of hospital admissions for HF has increased by more than 70% since 1980, from 42 965 admissions/year to 73 448 admissions/year in 1993.\(^2\)

Although the most common causes of this syndrome are hypertension and ischemic heart disease, any cause that chronically alters heart function (e.g., structural heart disease, valve disorders and diseases of the pericardium or great vessels) can lead to HF. Heart failure per se should not be taken as a final diagnosis, as there must exist an underlying disease—generally a structural heart disease. The prognosis for HF depends on appropriate management and treatment, although the presence of ventricular dysfunction per se indicates an unfavorable prognosis. Overall mortality from this syndrome at 5 years after the initial diagnosis is 50%, a figure that has remained practically unchanged in recent years despite advances in medical treatment. Although the treatment regimens for HF are well established and the favorable effects of certain drugs on the prognosis are well known, fewer than 50% of
the patients receive appropriate treatment according to evidence-based medical criteria. Only about one-third of all patients are given an electrocardiogram as part of the initial evaluation of HF, a shortcoming that has also been documented in Spain. The underuse of echocardiography in the initial diagnosis makes it difficult to detect those patients with systolic ventricular dysfunction, and hence delays appropriate treatment.

Heart failure is a clinical syndrome that is much more common in the elderly or very elderly. Mean age of the patients in the study by Soriano Palacios et al. published in this issue of ATENCIÓN PRIMARIA was 75 years; 57% of the patients were women. In a large hospital register assembled by internal medicine specialists --the SEMI-IC register--- mean age was 77 years and the sex distribution was the same as in the report by Soriano Palacios et al. In another study done within the primary care setting --the ICAP study--- mean age was slightly lower at 72 years, 61% of the patients were women, and mean functional class was better. However, all studies reported a high rate of comorbidity (chronic obstructive lung disease, diabetes, renal failure, etc). This contrasts with data from clinical trials, including some of the most recent studies (e.g., CIBIS-II, MERIT-HF, RALES and ValHeFT), in which mean age was 62 years, men predominated (80%), and comorbidity (often an exclusion criterion in clinical trials) was low. The etiology of HF in patients included in clinical trials is mainly ischemic, whereas in patients with HF being treated in the community the most common etiology is hypertension, at least in Spain (a circumstance also reflected in the present study, in the ICAP study and in the SEMI-IC register).

The difference in profile between patients included in clinical trials versus those seen in daily practice is not a feature exclusive to HF, but is a rather common feature of cardiovascular diseases. However, this difference is likely to have a notable influence on decision making with regard to evidence-based pharmacological treatment for patients in the community. A clear and noteworthy example is the use of beta-blockers for chronic HF (carvedilol, bisoprolol and metoprolol); these drugs have shown an unequivocally positive impact on prognosis, reducing overall mortality by 30% in different trials and meta-analyses, and ameliorating morbidity and stability (i.e., readmission, functional class, etc). Paradoxically, beta-blockers are still currently used for fewer than 15% of all patients with HF. Perhaps, as the present study suggests, the classical assumption that these drugs are contraindicated in HF still persists. Further problems are posed by the process of introducing treatment with these drugs in daily practice: contraindications (relative and absolute), the advanced age of most patients, comorbidity, problems with dose titration (which must be done with great care, and only when the patient’s condition is stable), and finally the lack of coordination between specialized care (hospital or extrahospital services) and primary care. Implementing treatment with beta-blockers in most patients who are candidates for these drugs is a process that requires close, efficient coordination between the cardiologist or internal medicine specialist and the primary care physician. It will not be possible to extend treatment with beta-blockers to a suitable proportion of patients until primary care physicians are actively involved in follow-up. The HF units now in operation at some hospitals may start treatment with beta-blockers in certain selected patients, but the current magnitude of and future perspectives for the incidence of HF in the Western world require a multidisciplinary focus for this problem, and coordinated management of patients to optimize the clinical benefits.

A previous study found not only that beta-blockers were underused (possibly explainable, as the authors suggest, by the fact that the relevant studies had only just been published at the time), but also that the use of angiotensin-converting enzyme (ACE) inhibitors, considered the cornerstone of treatment for HF, was less than optimal. In many patients (33%) no echocardiogram (or any other test of ventricular function) had been done; the information provided by such tests is fundamental to determine whether systolic or diastolic dysfunction is present, to choose the best approach to therapy, to rule out potentially correctable causes of HF, and to arrive at a prognosis. Moreover, a large proportion of patients in the present study had normal systolic function (42%), a finding also reported in earlier studies and related with the higher prevalence of diastolic dysfunction in older patients. Angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists (ARA-II) were prescribed for 72% of the patients with a documented reduction in ejection fraction, as compared to 46% of the patients in whom ejection fraction was preserved. Several studies have shown that ACE inhibitors are underused in clinical practice, both in hospitals and in primary care. This is a problem that still awaits solution. In addition, the study by Soriano Palacios et al. shows that during the 18-month follow-up period, ACE inhibitors were the type of drug substituted or stopped most often, which they attribute in great measure to the adverse effects of these medications. The poor prognosis of HF related with the syndrome itself, and—to a non-negligible extent (20%)—with comorbidity, probably undermined enthusiasm for treatments that might not have been tolerated well. In any case the prognosis for HF is unfavorable, as noted in other studies and emphasized once again here. Although improving the prognosis is a prime goal of treatment, it is no less important to maintain or improve, if possible, the quality of life, and to prevent frequent hospital readmissions (38.5% of the patients).

In this connection the role of the family doctor in follow-up is crucial in maintaining the patient stable and living at home for as long as possible. The physician consulted most
often after hospital discharge was the family doctor, followed by hospital out-patient staff (note, however, that 19% of the patients were participating in clinical trials). Follow-up was not handled by any one physician exclusively, but was shared with specialists in internal medicine or cardiology. The primary care service is a privileged vantage point for the follow-up of these patients, who will usually need close clinical surveillance with frequent dose adjustments (especially for diuretics). Also important in follow-up care are such simple elements as appropriate educational measures for patients and their families, including control of body weight and information aimed at optimizing treatment compliance.9

It is difficult to develop a fixed protocol for the clinical follow-up of all patients with HF. Most patients will require adjustments in the dose of ACE inhibitors (often, the optimum dose is not attained during the hospital stay, mainly because short stays do not allow enough time for this), and the dose of diuretics must also be adjusted as the patient’s symptoms are brought under control. In patients with functional class III-IV HF, low dose spironolactone (12.5-25.0 mg/day) should be considered, although this requires close vigilance of renal function and serum potassium concentrations. The usefulness of periodic echocardiograms or chest x-rays in follow-up has not been established (except for decompensated patients, and only when the need for repeat tests is based on the clinical findings). However, the value of creatinin and potassium ion measurements (7 to 10 days after discharge initially, and after 2-3 months in patients who remain stable) is unquestioned. If there are no contraindications, patients who are stable should be evaluated for treatment with beta-blockers by clinicians trained in the use of these drugs, and such treatment should be coordinated in conjunction with the family physician.

Reference